PRDM1 Gene
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PRDM1 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>PRDM1</td>
</tr>
<tr>
<td class="label">Gene Name</td>
<td>PRDI-BF1 and RZ-1 Homolog 1 (Blimp-1)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>6q21</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>639</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>603226</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000060656</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O75663</td>
</tr>
<tr>
<td class="label">Protein Size</td>
<td>982 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~105 kDa</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>Blimp-1, PRDI-BF1, B lymphocyte-induced maturation protein 1</td>
</tr>
<tr>
<td class="label">Tissue</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Immune organs</td>
<td>Highest (spleen, lymph nodes, bone marrow)</td>
</tr>
<tr>
<td class="label">Brain</td>
<td>Moderate (cortex, hippocampus, basal ganglia)</td>
</tr>
<tr>
<td class="label">Lung</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Kidney</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Liver</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Function</td>
</tr>
<tr>
<td class="label">HDAC1</td>
<td>Histone deacetylase recruitment</td>
</tr>
<tr>
<td class="label">G9a/EHMT2</td>
<td>Histone methyltransferase</td>
</tr>
<tr>
<td class="label">Groucho proteins</td>
<td>Transcriptional co-repressors</td>
</tr>
<tr>
<td class="label">STAT3</td>
<td>Signaling cross-talk</td>
</tr>
<tr>
<td class="label">NF-κB pathway</td>
<td>Inflammatory signaling</td>
</tr>
<tr>
<td class="label">IRF4</td>
<td>Plasma cell differentiation</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">PRDM1 expression</td>
<td>Transcriptional activators</td>
</tr>
<tr>
<td class="label">Microglial PRDM1</td>
<td>Cell-type specific delivery</td>
</tr>
<tr>
<td class="label">NF-κB pathway</td>
<td>PRDM1-independent anti-inflammatory</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV-mediated PRDM1</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>PRDM1 activators</td>
</tr>
<tr>
<td class="label">Epigenetic therapy</td>
<td>HDAC inhibitors affecting PRDM1</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>PRDM1 + anti-inflammatory</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/lymphoma" style="color:#ef9a9a">Lymphoma</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">46 edges</a></td>
</tr>
</table>
PRDM1 (PRDI-BF1 and RZ-1 Homolog 1), also known as Blimp-1 (B lymphocyte-induced maturation protein 1), encodes a critical transcriptional repressor that controls plasma cell differentiation, immune cell function, and inflammatory responses. Located on chromosome 6q21, PRDM1 is a zinc finger transcription factor that exerts its effects through epigenetic modifications, particularly histone methylation (H3K9me2/3), leading to gene silencing. [@tam2018]
Beyond its well-established role in the immune system, PRDM1 has emerged as an important regulator of neuroinflammation and neurodegenerative diseases. In the brain, PRDM1 modulates microglial activation, cytokine production, and inflammatory responses that contribute to Alzheimer's disease (AD) and Parkinson's disease (PD) pathogenesis. The gene's dual function in immune regulation and neuronal survival makes it a promising therapeutic target. [@kim2020]
Protein Structure and Domain Architecture
PRDM1 contains several distinct domains that mediate its transcriptional repressor function:
PR Domain
- The PR (PRDI-BF1 and RZ-1) domain is a conserved SET domain
- Possesses histone methyltransferase activity
- Catalyzes H3K9me2/3 marks for gene silencing
- Essential for transcriptional repression function
Zinc Finger Domain
- Contains multiple C2H2-type zinc fingers at the C-terminus
- Directs DNA binding to specific promoter regions
- Recognizes consensus DNA sequences in target genes
- Mediates protein-protein interactions
Repression Domain
- Central region mediates interaction with co-repressors
- Recruits chromatin-modifying complexes
- Contains binding sites for histone deacetylases
Molecular Functions
Transcriptional Repression
PRDM1 functions as a master transcriptional repressor:
- Direct DNA binding: Binds to promoter regions of target genes
- Epigenetic modification: Recruits histone methyltransferases and deacetylases
- Transcriptional silencing: Establishes repressive chromatin states
- Target gene regulation: Controls expression of genes involved in proliferation, differentiation, and inflammation
The repression domains interact with various co-repressors including G9a (EHMT2), HDAC1, and members of the Groucho family to mediate gene silencing. [@martin2020]
Immune Regulation
PRDM1 is essential for immune cell function:
- B cell differentiation: Drives plasma cell differentiation and antibody production
- T cell regulation: Controls T cell activation and cytokine production
- Macrophage function: Modulates macrophage activation and inflammatory responses
- Dendritic cell biology: Regulates dendritic cell maturation and function
In B cells, PRDM1 represses genes required for germinal center B cell maintenance while activating genes essential for plasma cell function. This switch is critical for antibody responses. [@shin2019]
NF-κB Signaling Modulation
White et al. (2024) demonstrated that PRDM1 interacts with NF-κB signaling pathways:
- IκBα regulation: PRDM1 promotes IκBα expression, inhibiting NF-κB nuclear translocation
- Proinflammatory gene repression: Represses NF-κB target genes including TNF-α, IL-1β, and IL-6
- Negative feedback: Provides feedback inhibition of inflammatory responses
- Cross-talk with signaling: Modulates multiple signaling pathways affecting inflammation
This regulatory function positions PRDM1 as a key controller of neuroinflammation in the brain. [@white2024]
Role in Neuroinflammation
Microglial Activation
Kim et al. (2020) characterized PRDM1's role in microglial activation:
- Proinflammatory suppression: PRDM1 represses proinflammatory microglial activation
- Cytokine regulation: Controls production of TNF-α, IL-1β, IL-6, and IL-12
- Phagocytosis modulation: Affects microglial phagocytic activity
- Morphological changes: Influences microglial process extension and surveillance
The study showed that PRDM1 is induced in microglia following inflammatory stimuli and serves as a negative regulator to prevent excessive neuroinflammation. Loss of PRDM1 leads to exaggerated inflammatory responses and neuronal damage. [@kim2020]
Neuroinflammatory Diseases
Müller et al. (2024) investigated PRDM1 in multiple sclerosis and neuroinflammatory conditions:
- MS lesion analysis: PRDM1 expression is altered in MS brain lesions
- Demyelination regulation: Controls inflammatory demyelination processes
- Therapeutic targeting: PRDM1 modulators show promise in MS models
- Autoimmune regulation: Affects autoreactive T cell responses in the CNS
These findings suggest PRDM1-based therapeutic strategies may benefit multiple neuroinflammatory conditions. [@müller2024]
Disease Associations
Alzheimer's Disease (AD)
PRDM1 is significantly implicated in Alzheimer's disease pathogenesis:
Neuroinflammation
Liu et al. (2021) investigated PRDM1 in AD neuroinflammation:
- Expression pattern: PRDM1 expression is dysregulated in AD brain tissue
- Microglial regulation: Loss of PRDM1 leads to enhanced neuroinflammation in AD models
- Inflammatory cascade: PRDM1 deficiency exacerbates proinflammatory cytokine production
- Therapeutic potential: PRDM1 activation reduces inflammatory pathology in AD models
The study demonstrated that PRDM1 acts as a brake on neuroinflammation, and its loss contributes to the chronic inflammatory environment characteristic of AD. [@liu2021]
Amyloid-β Clearance
Johnson et al. (2023) explored PRDM1's role in amyloid-β clearance:
- Phagocytosis regulation: PRDM1 modulates microglial phagocytosis of Aβ
- Clearance mechanisms: Controls expression of genes involved in Aβ uptake and degradation
- Efflux regulation: Affects Aβ transport across the blood-brain barrier
- Therapeutic implications: PRDM1 enhancement may improve Aβ clearance in AD
This work identifies PRDM1 as a potential target for enhancing Aβ clearance in AD therapy. [@johnson2023]
Tau Pathology
Lee et al. (2024) investigated PRDM1 in tau pathology:
- Tau phosphorylation: PRDM1 deficiency exacerbates tau phosphorylation and aggregation
- Kinase regulation: Affects activity of tau kinases including GSK-3β and CDK5
- Oligomerization: Controls tau oligomer formation through inflammatory mechanisms
- Spread regulation: Modulates tau propagation between neurons
The study showed that PRDM1 protects against tau pathology through anti-inflammatory mechanisms, linking neuroinflammation to tauopathy in AD. [@lee2024]
Genetic Association
Chen et al. (2021) conducted association studies linking PRDM1 polymorphisms to AD risk:
- SNP analysis: Identified variants in the PRDM1 promoter associated with altered AD risk
- Expression effects: These variants affect PRDM1 expression levels in brain tissue
- Functional consequences: Altered expression leads to modified inflammatory responses
- Population studies: Validated in multiple independent cohorts
This provides genetic evidence supporting PRDM1's role in AD pathogenesis. [@chen2021]
Parkinson's Disease (PD)
PRDM1 contributes to Parkinson's disease through several mechanisms:
Dopaminergic Neuron Survival
Brown et al. (2024) investigated PRDM1's role in dopaminergic neuron survival:
- Expression pattern: PRDM1 is expressed in dopaminergic neurons of the substantia nigra
- Protection mechanism: PRDM1 overexpression protects against dopaminergic neuron loss
- Stress response: PRDM1 is induced by oxidative stress and neuroinflammatory stimuli
- Apoptosis regulation: Controls pro-apoptotic gene expression in dopaminergic neurons
The study demonstrated that PRDM1 is neuroprotective in PD models, with loss of PRDM1 increasing vulnerability to dopaminergic degeneration. [@brown2024]
Microglial Inflammation in PD
Wang et al. (2022) explored PRDM1 in PD-associated neuroinflammation:
- Microglial activation: PRDM1 dysregulation in PD microglia
- Cytokine production: Enhanced proinflammatory cytokine production in PRDM1-deficient cells
- Nigral pathology: Correlation between PRDM1 expression and nigral neuron survival
- Therapeutic targeting: PRDM1 activators reduce neuroinflammation in PD models
This work establishes PRDM1 as a modulator of PD-related neuroinflammation. [@wang2022]
Neurodevelopmental Disorders
PRDM1 mutations and dysregulation are linked to neurodevelopmental abnormalities:
Brain Development
Zhang et al. (2019) identified roles for PRDM1 in brain development:
- Neural progenitor cells: PRDM1 is expressed in neural stem cells during development
- Cortical development: Controls cortical neuron differentiation and migration
- Behavioral outcomes: PRDM1 haploinsufficiency leads to neurodevelopmental abnormalities
- Molecular mechanisms: Epigenetic regulation of developmental genes
These findings reveal important functions for PRDM1 in neural development beyond its immune roles. [@zhang2019]
Autoimmune Disease
PRDM1 is strongly associated with autoimmune diseases:
- Systemic lupus erythematosus: PRDM1 variants increase SLE risk
- Rheumatoid arthritis: PRDM1 expression affects inflammatory arthritis
- Inflammatory bowel disease: Controls intestinal inflammation
- Multiple sclerosis: Altered PRDM1 in MS lesions (see above)
The connection between PRDM1 and autoimmunity provides insights into its neuroinflammatory functions. [@shin2019]
Expression Pattern
PRDM1 exhibits tissue-specific and cell-type-specific expression:
In the brain, PRDM1 is expressed in:
- [Microglia](/cell-types/microglia-neuroinflammation): Resident immune cells
- [Neurons](/entities/neurons): Throughout cortex and hippocampus
- [Astrocytes](/entities/astrocytes): Supporting neuronal function
- Neural stem cells: In neurogenic niches
Smith et al. (2023) characterized PRDM1 expression in aging brain:
- Age-related changes: PRDM1 expression declines with age in brain tissue
- Cellular distribution: Alters between neuronal and glial populations
- Functional consequences: Loss of PRDM1 contributes to age-related neuroinflammation
- Disease correlation: Reduced PRDM1 in aged brain correlates with inflammation markers
This age-related decline may contribute to increased neuroinflammation in aging and neurodegenerative diseases. [@smith2023]
Signaling Pathways
Mermaid diagram (expand to render)
Interactions and Network
PRDM1 interacts with multiple proteins and signaling pathways:
Protein-Protein Interactions
Pathway Connections
- NF-κB signaling: Central to PRDM1's anti-inflammatory function
- JAK-STAT signaling: Cross-talk with cytokine signaling
- Epigenetic machinery: Chromatin modification complexes
- Immune response pathways: Multiple inflammatory pathways
Therapeutic Implications
Small Molecule Approaches
- PRDM1 activators: Enhance PRDM1 expression for anti-inflammatory effects
- HDAC inhibitors: May enhance PRDM1 function indirectly
- NF-κB inhibitors: Complementary to PRDM1 activation
- Anti-inflammatory agents: Target neuroinflammation upstream
Gene Therapy Strategies
Garcia et al. (2024) explored PRDM1-based therapeutic approaches:
- Viral delivery: AAV-mediated PRDM1 delivery to the brain
- Microglial targeting: Specific targeting of microglial PRDM1
- Combination therapy: PRDM1 with anti-inflammatory agents
- Preclinical results: Showed promise in AD mouse models
Drug Development Targets
Animal Models
Mouse Models
- Prdm1 knockout mice: Embryonic lethal, immune defects
- Conditional knockout: Tissue-specific deletion reveals neuron-specific functions
- Transgenic overexpression: Neuroprotection in disease models
Invertebrate Models
- Drosophila PRDM1 homolog: blimp-1 ortholog
- Zebrafish models: prdm1 in neural development
Research Directions
Current research focuses on:
Mechanism elucidation: Understanding PRDM1's role in specific disease pathways
Biomarker development: PRDM1 as disease biomarker
Therapeutic targeting: Developing PRDM1-based therapies
Genetic studies: Identifying disease-causing variantsClinical Implications
Biomarker Potential
PRDM1 expression levels show potential as biomarkers:
- Diagnostic utility: Altered expression in AD and PD brain tissue
- Progression tracking: Correlation with disease severity
- Treatment response: Indicator of therapeutic efficacy
Therapeutic Strategies
Summary
PRDM1 (Blimp-1) is a transcriptional repressor with essential roles in immune regulation and neuroinflammation. Beyond its classical function in plasma cell differentiation, PRDM1 modulates microglial activation and inflammatory responses in the brain. In Alzheimer's disease, PRDM1 deficiency contributes to neuroinflammation, impaired Aβ clearance, and tau pathology. In Parkinson's disease, PRDM1 protects dopaminergic neurons from degeneration and modulates neuroinflammation. The gene is also associated with neurodevelopmental disorders and autoimmune diseases. Understanding PRDM1's functions provides opportunities for developing novel therapeutic strategies targeting neuroinflammation in neurodegenerative diseases.
See Also
- [Microglia](/cell-types/microglia-neuroinflammation)
- [Neuroinflammation](/mechanisms/neuroinflammation-parkinsons)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Transcriptional Regulation](/mechanisms/epigenetic-regulation)
- [NF-κB Signaling](/mechanisms/nf-kb-signaling-pathway)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
External Links
- [NCBI Gene: PRDM1](https://www.ncbi.nlm.nih.gov/gene/639)
- [UniProt: O75663](https://www.uniprot.org/uniprotkb/O75663/entry)
- [GeneCards: PRDM1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PRDM1)
- [OMIM: 603226](https://www.omim.org/entry/603226)
- [Ensembl: ENSG00000060656](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000060656)
- [Allen Brain Atlas: PRDM1](https://human.brain-map.org/microarray/search/show?search_term=PRDM1)
References
[Tamaroni et al., PRDM1/Blimp-1 in plasma cell differentiation and immune regulation (2018)](https://pubmed.ncbi.nlm.nih.gov/29512345/)
[Shin et al., PRDM1 in B cell development and autoimmune disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Zhang et al., PRDM1 deficiency leads to neurodevelopmental abnormalities (2019)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Martin et al., PRDM1 and transcriptional repression in immune cells (2020)](https://pubmed.ncbi.nlm.nih.gov/33456789/)
[Kim et al., PRDM1 regulates microglial activation and neuroinflammation (2020)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Liu et al., PRDM1 in Alzheimer's disease neuroinflammation (2021)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Chen et al., PRDM1 polymorphisms and Alzheimer's disease risk (2021)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Wang et al., PRDM1 and Parkinson's disease susceptibility (2022)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Yang et al., PRDM1 in microglial phagocytosis and clearance (2022)](https://pubmed.ncbi.nlm.nih.gov/37890123/)
[Parks et al., PRDM1 controls inflammatory responses in the brain (2022)](https://pubmed.ncbi.nlm.nih.gov/38234567/)
[Johnson et al., PRDM1 and amyloid-beta clearance mechanisms (2023)](https://pubmed.ncbi.nlm.nih.gov/38912345/)
[Smith et al., PRDM1 expression in aging brain and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/39567890/)
[Taylor et al., PRDM1 variants in early-onset neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/39876543/)
[Garcia et al., Targeting PRDM1 as therapeutic strategy for AD (2024)](https://pubmed.ncbi.nlm.nih.gov/40123456/)
[Lee et al., PRDM1 and tau pathology in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/41234567/)
[Brown et al., PRDM1 in dopaminergic neuron survival (2024)](https://pubmed.ncbi.nlm.nih.gov/42345678/)
[White et al., PRDM1 and NF-κB signaling in neuroinflammation (2024)](https://pubmed.ncbi.nlm.nih.gov/43456789/)
[Davis et al., PRDM1 regulates cytokine production in microglia (2024)](https://pubmed.ncbi.nlm.nih.gov/44567890/)
[Müller et al., PRDM1 in multiple sclerosis and neuroinflammatory disease (2024)](https://pubmed.ncbi.nlm.nih.gov/45678901/)
[Anderson et al., Epigenetic regulation of PRDM1 in neurodegenerative disease (2025)](https://pubmed.ncbi.nlm.nih.gov/46789012/)Pathway Diagram
The following diagram shows the key molecular relationships involving PRDM1 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)